Elanco Animal Health Incorporated $ELAN Shares Sold by Private Management Group Inc.

Key Points

• Private Management Group cut its Elanco stake by 12.7% in the third quarter, selling 86,075 shares and retaining 592,242 shares valued at about $13.3 million.
• Elanco reported quarterly EPS of $0.27 versus $0.20 expected and revenue of about $1.26 billion, up 11.3% year over year. The company also issued 2026 EPS guidance of $1.17–$1.20.
• Analyst views are broadly positive: the stock has a “Moderate Buy” consensus and an average price target of $29.75, though some firms recently lowered their targets or ratings.

Private Management Group Inc. trimmed its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 12.7% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 592,242 shares of the company's stock after selling 86,075 shares during the period. Private Management Group Inc. owned about 0.12% of Elanco Animal Health worth $13,260,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the business. BlackRock Inc. bought a new position in shares of Elanco Animal Health in the second quarter valued at $1,202,198,000. Primecap Management Co. CA bought a new stake in shares of Elanco Animal Health during the 2nd quarter worth $1,118,402,000. State Street Corp boosted its stake in shares of Elanco Animal Health by 4.7% during the 2nd quarter. State Street Corp now owns 16,063,046 shares of the company's stock worth $395,312,000 after acquiring an additional 726,567 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in shares of Elanco Animal Health in the 2nd quarter worth $205,636,000. Finally, Sei Investments Co. grew its holdings in shares of Elanco Animal Health by 737.5% in the 1st quarter. Sei Investments Co. now owns 5,650,393 shares of the company's stock worth $135,214,000 after acquiring an additional 4,975,721 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company's stock.

Elanco Animal Health Stock Up 4.2%

Shares of NYSE:ELAN opened at $26.82 on Tuesday. The firm has a 50 day simple moving average of $23.18 and a 200 day simple moving average of $23.84. Elanco Animal Health Incorporated has a 52 week low of $19.40 and a 52 week high of $27.98. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.10 and a current ratio of 2.05. The company has a market cap of $13.40 billion, a PE ratio of -89.41, a price-to-earnings-growth ratio of 2.25 and a beta of 1.73.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its quarterly earnings data on Friday, November 6th. The company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.07. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The firm had revenue of $1.26 billion for the quarter, compared to analysts' expectations of $1.21 billion. During the same period in the previous year, the company posted $0.19 EPS. The company's quarterly revenue was up 11.3% compared to the same quarter last year. Elanco Animal Health has set its Q4 2026 guidance at 0.160-0.190 EPS and its FY 2026 guidance at 1.170-1.200 EPS. As a group, research analysts expect that Elanco Animal Health Incorporated will post 1.13 earnings per share for the current year.

Analyst Ratings Changes

ELAN has been the topic of a number of recent analyst reports. Morgan Stanley cut their target price on Elanco Animal Health from $26.00 to $25.00 and set an "equal weight" rating on the stock in a research report on Thursday, October 29th. KeyCorp reiterated an "overweight" rating on shares of Elanco Animal Health in a research report on Monday. Jefferies Financial Group lowered Elanco Animal Health from a "buy" rating to a "hold" rating and decreased their price target for the company from $31.00 to $24.00 in a research report on Tuesday, October 20th. The Goldman Sachs Group assumed coverage on Elanco Animal Health in a research note on Friday, October 16th. They issued a "buy" rating and a $32.00 price target on the stock. Finally, Weiss Ratings upgraded Elanco Animal Health from a "sell (d)" rating to a "sell (d+)" rating in a report on Friday, September 4th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $29.75.

Key Stories Impacting Elanco Animal Health

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: JPMorgan raised its price target to $35 from $33 and reiterated an Overweight rating, implying about 30.5% upside from the cited $26.82 share price. JPMorgan price-target update
• Positive Sentiment: Elanco’s Q3 results topped consensus: earnings were $0.27 per share versus $0.20 expected, while revenue reached $1.27 billion versus $1.21 billion expected and grew 11.3% year over year. The company also reported 9% organic constant-currency revenue growth and reduced gross debt by $216 million, supporting the growth and balance-sheet outlook. Three takeaways for long-term investors
• Positive Sentiment: A consumer survey found pet health is among the expenses owners are least willing to cut, a potentially supportive demand signal for Elanco’s animal-health products. Survey on pet-health spending
• Neutral Sentiment: Elanco presented at the UBS Global Healthcare Conference, but the supplied report does not detail new guidance or material announcements from the presentation. UBS conference transcript
• Neutral Sentiment: News of a new chief people officer is a management update; no direct financial or operational impact was specified. Elanco and animal-health industry updates

Insiders Place Their Bets

In other Elanco Animal Health news, Director Lawrence Kurzius bought 40,000 shares of the stock in a transaction on Thursday, August 20th. The shares were bought at an average price of $23.40 per share, with a total value of $936,000.00. Following the purchase, the director directly owned 188,647 shares in the company, valued at $4,414,339.80. The trade was a 26.91% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Shiv O'Neill bought 3,998 shares of the stock in a transaction on Tuesday, August 18th. The shares were acquired at an average cost of $23.58 per share, for a total transaction of $94,272.84. Following the purchase, the insider owned 87,832 shares in the company, valued at approximately $2,071,078.56. This represents a 4.77% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought a total of 48,998 shares of company stock valued at $1,139,373 over the last ninety days. Corporate insiders own 1.14% of the company's stock.

Elanco Animal Health Company Profile

Elanco Animal Health is a global animal health company that develops, manufactures and markets products for companion animals and livestock. Its offerings include medicines, vaccines and other products intended to prevent and treat disease and support animal health.

For pets, Elanco provides treatments for conditions including parasitic infections, pain and chronic diseases. Its livestock products support the health of animals such as cattle, poultry, swine and fish, serving producers and veterinarians.

The company traces its origins to Eli Lilly's animal health business, established in 1954, and became an independent public company in 2018.

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.